First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 207 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Vimseltinib September 5, 2025 Couple Buys Customized SUV To Give Free Rides To Critically Ill... September 11, 2019 Sister Is There To Comfort Her Little Brother As He Battles... September 10, 2019 Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... February 11, 2022 Load more HOT NEWS FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced... Study Finds the Cost of Treating Metastatic Breast Cancer Could More...
